Abstract

PEMPHIGUS VULGARIS: AN OVERVIEW

Neha Rangwar*, Harshitha Kasavarjala, Pushpendra Kumar, Rewak Tyagi, Ruchi Priya and Shaikh Mohmed Adnan Mohmed Javid

.

Abstract

Rare autoimmune illnesses affecting the skin and mucous membranes are known as pemphigus. The skin and mucous membrane epithelium can develop vesicles and erosions due to these intraepidermal bullous diseases. Pemphigus vulgaris accounts for up to 70% of all cases, as is widely recognised. One of the first symptoms that patients may experience is the development of highly painful erosions on their mucosal membranes. The epidemiology of pemphigus varies substantially across the world. The prognosis, mortality rate, and clinical outcomes for pemphigus patients have evolved significantly. Erosion of the oral mucosa and subsequent skin involvement are common symptoms in patients with PV. It takes a long time for aphthous ulceration and other cutaneous symptoms of the illness to manifest since they usually show up after mucosal erosions have already happened. Osteoporosis is one of the infamous side effects of systemic corticosteroids, which are used in the treatment of pemphigus vulgaris. Systemic corticosteroids continue to play a pivotal role in treating pemphigus vulgaris (PV) due to their significant impact on PV management.

Keywords: Immunoglobulin G, Paraneoplastic pemphigus, Corticosteroids, and Pemphigus vulgaris.